Facilitated By

San Antonio Medical Foundation

The AIM-HN And SEQ-HN Study: A 2 Cohort, Non-Comparative, Pivotal Study Evaluating The Efficacy Of Tipifarnib In Patients With Head And Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) And The Impact Of HRAS Mutations On Response To First Line Systemic Therapies For HNSCC (SEQ-HN)

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Research Start Date
Status
Active

The primary objective of this study (KO-TIP-007) is to determine the overall response rate (ORR) of Tipifarnib in subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) with Harvey rat sarcoma virus gene homolog (HRAS) mutations as assessed by Independent Review Facility (IRF).

Collaborative Project
Clinical Care
Cancer
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.